Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL - report from ASH2023

Professor Peter Hillmen on the combination of ibrutinib and venetoclax, at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia, according to findings from the phase 3 FLAIR trial that were presented at the 2023 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:ibrutinib-plus-venetoclax-mrd-directed-duration-treatment-superior-fcr-and-new-standard-care-previously-untreated-cll